Effect of Roflumilast on Exacerbation Rate in Patients With COPD. The HERMES Study
Effect of Roflumilast on Exacerbation Rate in Patients With COPD. The HERMES Study
The aim of the study is to compare the effect of roflumilast on exacerbation rate and pulmonary function in patients with chronic obstructive pulmonary disease (COPD). Roflumilast will be administered orally once daily in the morning at one dose level. The study duration will be up to 56 weeks. The study will provide further data on safety and tolerability of roflumilast.
For additional information (for US patients only) see www.COPDSTUDY.net or dial 866-788-2673 (toll free).
Main Inclusion Criteria:
Main Exclusion Criteria:
Washington D.C., District of Columbia 20017, United States
Ormand Beach, Florida 32174, United States
Ste-Foy, Quebec G1W 4R4, Canada
Ontario, L2R2Z9, Canada
Landsberg/Lech, 86899, Germany
Mumbai, Byculla, 400 008, India
Mumbai, Dadar (E), 400 014, India
Shastri Nagar, Jaipur, 302 016, India
Cassano Murge, 70020, Italy
Bellville, Cape Town, 7530, South Africa
Berea, Durban, 4000, South Africa
C/O Netcare & Garsfontein Roads, 44, South Africa
Durban, Amanzimtoti, 4126, South Africa
Durbanville / Cape Town, 7550, South Africa
Mowbray, Cape Town, 7925, South Africa
Paarl, Cape Town, 7626, South Africa
Partida de Bacarot (Alicante), 3114, Spain
Tarrasa (Barcelona), 8221, Spain
Toldeo, 45004, Spain